Meet our Product Experts
Human Cells for Drug Discovery
Monday February 5, 2018
11:30 AM - 11:50 AM
Meet with our product experts, discuss your questions, find out about our latest human iPSC-derived product innovations and their potential contribution in the drug discovery and pain research.
Late Night with LRIG Drug Discovery
Drug Discovery and Life Science to the Core
Do human iPSC-derived Renal Proximal Tubular Cells provide an answer for predicting nephrotoxicity?
Monday February 5, 2018
6:00 PM - 8:00 PM
Late Night Overview
A rapid-fire innovation session between Axol Bioscience and LRIG Drug Discovery delegates, with human iPSC-derived Renal Proximal Tubular Cells and their use in nephrotoxicity to be the keystone of the discussion.
Run by Axol Bioscience
Stem Cell-derived Human Renal Cells for Compound Screening and Nephrotoxicity Prediction
Tuesday February 6, 2018
12:30 PM - 1:45 PM
Room 1A (Located on the upper level of the San Diego Convention Center)
The kidney is a main target organ for compound-induced toxicity. Recently, we have developed the first pre-validated screening platforms for the accurate prediction of nephrotoxicity in humans (Li et al., Toxicol. Res., 2013; Li et al., Mol. Pharm., 2014; Su et al., BMC Bioinformatics, 2014; Kandasamy et al., Sci. Rep., 2015; Su et al., Arch. Toxicol., 2016; Chuah & Zink, Biotechnol. Adv, 2017; Loo & Zink, Altern. Lab. Anim., 2017). These platforms include the only available predictive methods based on human induced pluripotent stem cell (iPSC)-derived renal cells (Kandasamy et al., 2015; Chuah & Zink, 2017). A protocol has been developed for the rapid generation of iPSC-derived human renal proximal tubular cell (PTC)-like cells. PTC-like cells with a purity of >90% can be obtained within only 8 days of differentiation and these cells can be directly applied for compound screening (Kandasamy et al., 2015). Alternatively, the cells can be cryopreserved. When assays based on iPSC-derived PTC-like cells were combined with machine learning techniques, compound-induced nephrotoxicity could be predicted with a test balanced accuracy of 87% (Kandasamy et al., 2015). In addition, compound-induced injury mechanisms and cellular pathways were correctly identified. PTC-like cells would be also suitable for applications in our recently developed high-throughput platform (Su et al., 2016; Chuah & Zink, 2017). This high-throughput platform predicts nephrotoxicity in humans with a test balanced accuracy of ~80% - 90% depending on the cell type used (Su et al., 2016; Loo & Zink, 2017), and is currently applied in collaboration with the US Environmental Protection Agency to predict the human nephrotoxicity of ToxCast compounds. Currently we are developing kidney-on-chip technologies for repeated dose testing and prediction of the human dose response.
Axol Bioscience in order to discuss the above topic is hosting Dr Daniele Zink , whose research focuses on stem cells and predictive methods for in vitro toxicology/nanotoxicology.
Register your interest below for updates on the latest news about our workshop.